These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24093809)

  • 21. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
    Solomon MM; Mayer KH; Glidden DV; Liu AY; McMahan VM; Guanira JV; Chariyalertsak S; Fernandez T; Grant RM;
    Clin Infect Dis; 2014 Oct; 59(7):1020-6. PubMed ID: 24928295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.
    Ware NC; Wyatt MA; Haberer JE; Baeten JM; Kintu A; Psaros C; Safren S; Tumwesigye E; Celum CL; Bangsberg DR
    J Acquir Immune Defic Syndr; 2012 Apr; 59(5):463-8. PubMed ID: 22267018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
    Donnell D; Baeten JM; Bumpus NN; Brantley J; Bangsberg DR; Haberer JE; Mujugira A; Mugo N; Ndase P; Hendrix C; Celum C
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):340-8. PubMed ID: 24784763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.
    Buchbinder SP; Glidden DV; Liu AY; McMahan V; Guanira JV; Mayer KH; Goicochea P; Grant RM
    Lancet Infect Dis; 2014 Jun; 14(6):468-75. PubMed ID: 24613084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States.
    Liu AY; Vittinghoff E; Chillag K; Mayer K; Thompson M; Grohskopf L; Colfax G; Pathak S; Gvetadze R; Oʼhara B; Collins B; Ackers M; Paxton L; Buchbinder SP
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):87-94. PubMed ID: 23481668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
    Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
    AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment.
    R Amico K; McMahan V; Goicochea P; Vargas L; Marcus JL; Grant RM; Liu A
    AIDS Behav; 2012 Jul; 16(5):1243-59. PubMed ID: 22460228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
    Haberer JE; Baeten JM; Campbell J; Wangisi J; Katabira E; Ronald A; Tumwesigye E; Psaros C; Safren SA; Ware NC; Thomas KK; Donnell D; Krows M; Kidoguchi L; Celum C; Bangsberg DR
    PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
    Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation.
    Liu AY; Hessol NA; Vittinghoff E; Amico KR; Kroboth E; Fuchs J; Irvin R; Sineath RC; Sanchez T; Sullivan PS; Buchbinder SP
    AIDS Patient Care STDS; 2014 Dec; 28(12):622-7. PubMed ID: 25396706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.
    Corneli A; Wang M; Agot K; Ahmed K; Lombaard J; Van Damme L;
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):555-63. PubMed ID: 25393942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
    Dolling D; Phillips AN; Delpech V; Pillay D; Cane PA; Crook AM; Shepherd J; Fearnhill E; Hill T; Dunn D; ;
    HIV Med; 2012 May; 13(5):309-14. PubMed ID: 22151684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.
    Corneli AL; McKenna K; Perry B; Ahmed K; Agot K; Malamatsho F; Skhosana J; Odhiambo J; Van Damme L
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):578-84. PubMed ID: 25761233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.